New stomach acid drug could boost h. pylori cure rates

NCT ID NCT06851468

Completed Disease control Sponsor: Key Laboratory for Gastrointestinal Diseases of Gansu Province Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed study tested whether a new drug called keverprazan, combined with the antibiotic amoxicillin, can effectively treat a first-time H. pylori infection in adults. 264 participants took either keverprazan or esomeprazole (a standard acid reducer) plus amoxicillin for 14 days. Researchers measured how many people were cured and tracked side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Keverprazan (a drug that reduces stomach acid, similar to esomeprazole)
What this could lead to: If successful, keverprazan could offer a new treatment option for first-time H. pylori infections, potentially improving eradication rates.
What could go wrong: This is a completed trial, but results are not yet published. The study is relatively small (264 participants) and only includes first-time infections, so findings may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HELICOBACTER PYLORI are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Helicobacter pylori infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HELICOBACTER PYLORI

Contacts and locations

Locations

KeyLabGIDiseasesGansu

Lanzhou, Gansu, 730000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.